Taxonomy

CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT

Finding Your Gene Researchers have discovered over 120 genes linked

2024 CMTA Patient & Research Summit Registration is Now Open

The 2024 CMTA Patient & Research Summit will take place

CMTA Announces New Center of Excellence in the United Kingdom

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of

New Law Makes Flying Easier for People Living With Charcot-Marie-Tooth Disease

A partnership between the Charcot-Marie-Tooth Association (CMTA), Muscular Dystrophy Association

CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

TAKE ACTION! Sign the Petition to Accelerate CMT-SORD

What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding,

CMTA Announces Addition of Health Insurance Industry Veteran Wendy Arnone to the Board of Directors

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

Evolution: CMTA Board Welcomes Coulie & Marks

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

CMTA Spring 2024 Report: Progress and Impact that Empowers Communities

VIEW IN BROWSER Sue Bruhn, the CEO of CMTA, expresses